Scientists
discover depression gene PDE4B
Nov 20, 2005
Revealing their findings in Science magazine, researchers have found a
damaged PDE4B gene effects how the brain thinks. This is another
important breakthrough in our still limited understanding of major mental illness,
said Professor David Porteous from the University of Edinburgh. It is the result
of a long term research commitment to use the tools of genetics to better understand
the root causes of mental disorder. Our insights into the important role
that the protein may play in the mis-function of the brain that leads to schizophrenia
will lead our thinking in the development of new treatments for this disorder.
In 2000, a research team from the University of Edinburgh
identified a gene known as Disrupted in Schizophrenia
One (DISC1).which was found to increase the chance
of people developing schizophrenia, clinical depression
and bipolar disorder (manic depression). In the team's
latest study they have found another similar gene -
phosphodiesterase 4B (PDE4B) - which could also increase
the risk of mental illness if damaged. The scientists
say the extent of the damage influences the type and
severity of illness a person has.
However, the researchers also pointed out that environmental
factors could also influence the chances of an individual
developing mental illness. The researchers concluded:
It is now clear that the DISC1 gene plays an important
role in the risk of developing schizophrenia or bipolar
affective disorder. 'The new genetic link we have made
to PDE4B and how that links back to DISC1 sheds much
needed light on these debilitating disorders. It also
suggests a new way of thinking about developing new
medicines. The Scots researchers worked alongside scientists
from pharmaceutical company Merck, Sharp & Dohme
Limited. Peter Hutson from Merck Sharp & Dohme,
said: Mental illness remains a scourge of society.
Our insights into the important role that the proteins
PDE4B and DISC1 may play in the mis-function of the
brain that leads to schizophrenia will lead our thinking
in the development of new treatments for this disorder.